Breaking News Instant updates and real-time market news.

OBSV

ObsEva

$16.87

(0.00%)

16:20
10/09/18
10/09
16:20
10/09/18
16:20

ObsEva presents clinical data from Phase 3 trial of Nolasiban

ObsEva announced that IMPLANT 2 Phase 3 clinical data of its novel, oral, oxytocin receptor antagonist, nolasiban, in patients undergoing IVF were presented at the 74th annual meeting of the American Society of Reproductive Medicine, taking place in Denver, Colorado, October 6-10, 2018. In the oral presentation entitled "A Placebo-controlled, Randomized, Double Blind, Phase 3 Study Assessing Ongoing Pregnancy Rates After Single Oral Administration of a Novel Oxytocin Receptor Antagonist, Nolasiban, Prior to Single Embryo Transfer" the primary endpoint results of the IMPLANT 2 trial showed an improvement in the rate of ongoing pregnancy 10 weeks post either Day 3 or Day 5 ET, with nolasiban treatment vs. placebo, 35.6% vs. 28.5%, a 25% increase. For women undergoing Day 5 ET, nolasiban resulted in an ongoing pregnancy rate of 45.9% vs. 34.7% for placebo, a 32% increase. Importantly, the tolerability and safety profile of nolasiban has been observed to be comparable to placebo, with no increase in serious adverse events, in ectopic pregnancy, nor in congenital birth defects. In addition, a secondary endpoint of miscarriage rate from weeks 2 to 24 of gestation showed a favourable impact from nolasiban treatment suggesting a reduced miscarriage rate following nolasiban treatment compared to placebo.

OBSV ObsEva
$16.87

(0.00%)

08/15/18
LEER
08/15/18
INITIATION
Target $25
LEER
Outperform
ObsEva resumed with an Outperform at Leerink
Leerink analyst Ami Fadia resumed coverage of ObsEva with an Outperform rating and $25 price target. The analyst believes that at current levels the stock does not fully reflect the commercial potential of its lead product linzagolix, which she believes can reach over $1B in peak sales, its additional women's health pipeline, and its more than $100M cash balance that can fund operation into 1H20, by which time she expects to get positive UF Phase 3 data readout for linzagolix.
08/15/18
08/15/18
INITIATION

On The Fly: Top five analyst initiations
Catch up on today's top five analyst initiations with this list compiled by The Fly: 1. Cision (CISN) initiated with an Outperform at William Blair. 2. ObsEva (OBSV) resumed with an Outperform at Leerink. 3. Idera Pharmaceuticals (IDRA) resumed with an Overweight at JPMorgan. 4. DTE Energy (DTE) initiated with an Equal Weight at Barclays. 5. Tellurian (TELL) initiated with an Outperform at Baird. This list is just a portion of The Fly's analyst coverage. To see The Fly's full Street Research coverage, click here.
08/29/18
HCWC
08/29/18
NO CHANGE
Target $44
HCWC
Buy
AbbVie study of elagolix reduces risk for ObsEva, says H.C. Wainwright
H.C. Wainwright analyst Raghuram Selvaraju believes AbbVie's (ABBV) long-term safety extension study of elagolix in women with uterine fibroids reduces risk for ObsEva (OBSV). The long-term efficacy for elagolix should bode well for future development of ObsEva's linzagolix in uterine fibroids, since both drugs are gonadotropin-releasing hormone receptor antagonists and have thus far shown comparable potency in clinical studies, Selvaraju tells investors in a research note. The analyst reiterates a Buy rating on ObsEva with a $44 price target.
09/13/18
JPMS
09/13/18
INITIATION
Target $29
JPMS
Overweight
ObsEva initiated with an Overweight at JPMorgan
JPMorgan analyst Eric Joseph started ObsEva with an Overweight rating and $29 price target. The analyst views ObsEva as an "underappreciated, emerging clinical-stage player" in the women's health space. The company has two pivotal stage assets addressing "significant commercial opportunities, and wholly owned rights in major markets," Joseph tells investors in a research note.

TODAY'S FREE FLY STORIES

$NYE

NYSE Market Internals

$0.00

(0.00%)

11:16
02/20/19
02/20
11:16
02/20/19
11:16
Technical Analysis
NYSE market internals summary »

Volume is average for…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

SN

Sanchez Energy

$0.36

(0.00%)

11:14
02/20/19
02/20
11:14
02/20/19
11:14
Hot Stocks
NYSE to suspend trading in Sanchez Energy, commence delisting proceedings »

The New York Stock…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 22

    May

AAOI

Applied Optoelectronics

$15.10

0.175 (1.17%)

11:10
02/20/19
02/20
11:10
02/20/19
11:10
Options
Applied Optoelectronics attracts a defensive option play ahead of earnings »

Applied Optoelectronics…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 21

    Feb

  • 21

    Feb

  • 26

    Feb

  • 27

    Feb

  • 28

    Feb

11:10
02/20/19
02/20
11:10
02/20/19
11:10
General news
Oil Action: WTI crude »

Oil Action: WTI crude has…

CVS

CVS Health

$64.96

-4.96 (-7.09%)

, RAD

Rite Aid

$0.77

-0.0121 (-1.56%)

11:08
02/20/19
02/20
11:08
02/20/19
11:08
On The Fly
CVS plunges on weaker guidance after closing Aetna acquisition »

Shares of CVS Health…

CVS

CVS Health

$64.96

-4.96 (-7.09%)

RAD

Rite Aid

$0.77

-0.0121 (-1.56%)

CI

Cigna

$195.38

-2.8 (-1.41%)

UNH

UnitedHealth

$269.15

-1.11 (-0.41%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 20

    Feb

  • 20

    Feb

  • 22

    Feb

  • 27

    Feb

  • 27

    Feb

  • 28

    May

MGLN

Magellan Health

$65.33

0.28 (0.43%)

11:05
02/20/19
02/20
11:05
02/20/19
11:05
Hot Stocks
Breaking Hot Stocks news story on Magellan Health »

Magellan Health jumps…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 28

    Feb

  • 28

    Feb

MGLN

Magellan Health

$65.33

0.28 (0.43%)

11:05
02/20/19
02/20
11:05
02/20/19
11:05
Periodicals
Breaking Periodicals news story on Magellan Health »

Magellan Health exploring…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 28

    Feb

  • 28

    Feb

WIX

Wix.com

$111.78

-13.92 (-11.07%)

11:05
02/20/19
02/20
11:05
02/20/19
11:05
Downgrade
Wix.com rating change  »

Rosenblatt downgrades…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 20

    Feb

  • 20

    Feb

  • 25

    Feb

  • 25

    Feb

  • 12

    Mar

  • 18

    Mar

TKC

Turkcell

$6.97

0.06 (0.87%)

11:02
02/20/19
02/20
11:02
02/20/19
11:02
Earnings
Turkcell reports FY net income 2.02B liras, consensus 1.93B liras »

Bloomberg reports that…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 20

    Feb

  • 14

    Mar

  • 19

    Mar

VIA

Viacom

$34.98

0.13 (0.37%)

, VIAB

Viacom

$29.35

0.22 (0.76%)

11:02
02/20/19
02/20
11:02
02/20/19
11:02
Hot Stocks
Viacom, fuboTV announce distribution partnership »

Viacom and fuboTV…

VIA

Viacom

$34.98

0.13 (0.37%)

VIAB

Viacom

$29.35

0.22 (0.76%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 20

    Feb

  • 27

    Feb

  • 04

    Mar

  • 11

    Mar

  • 11

    Mar

  • 11

    Mar

  • 11

    Mar

  • 06

    Jun

HRL

Hormel Foods

$42.86

-0.45 (-1.04%)

11:00
02/20/19
02/20
11:00
02/20/19
11:00
Options
Put buyers gobble up positions in Hormel Foods ahead of earnings »

Put buyers gobble up…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 21

    Feb

  • 21

    Feb

WIX

Wix.com

$112.09

-13.61 (-10.83%)

10:56
02/20/19
02/20
10:56
02/20/19
10:56
Downgrade
Wix.com rating change  »

Wix.com downgraded to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 20

    Feb

  • 20

    Feb

  • 25

    Feb

  • 25

    Feb

  • 12

    Mar

  • 18

    Mar

SJM

J.M. Smucker

$106.49

2.47 (2.37%)

10:54
02/20/19
02/20
10:54
02/20/19
10:54
Earnings
J.M. Smucker issues preliminary FY20 adjusted EPS growth outlook of 3%-4% »

In slides for its…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 20

    Feb

  • 20

    Feb

  • 26

    Feb

SJM

J.M. Smucker

$106.08

2.06 (1.98%)

10:52
02/20/19
02/20
10:52
02/20/19
10:52
Hot Stocks
J.M. Smucker sees FY20 outlook helped by pet prices, hurt by peanut butter price »

In slides for its…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 20

    Feb

  • 20

    Feb

  • 26

    Feb

ETM

Entercom

$7.73

0.22 (2.93%)

10:50
02/20/19
02/20
10:50
02/20/19
10:50
Options
Pre-earnings call buying in Entercom Communications »

Pre-earnings call buying…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 22

    Feb

  • 22

    Feb

SJM

J.M. Smucker

$106.00

1.98 (1.90%)

10:48
02/20/19
02/20
10:48
02/20/19
10:48
Earnings
J.M. Smucker repeats FY19 adjusted EPS view of $8.00-$8.20, consensus $8.01 »

In slides for its…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 20

    Feb

  • 20

    Feb

  • 26

    Feb

TGEN

Tecogen

$3.84

(0.00%)

10:48
02/20/19
02/20
10:48
02/20/19
10:48
Hot Stocks
Tecogen secures $8.4M trigeneration project in Manhattan »

Tecogen announced an…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

TKC

Turkcell

$6.97

0.06 (0.87%)

10:47
02/20/19
02/20
10:47
02/20/19
10:47
Hot Stocks
Breaking Hot Stocks news story on Turkcell »

Turkcell trading halted,…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 20

    Feb

  • 14

    Mar

  • 19

    Mar

HON

Honeywell

$153.66

0.39 (0.25%)

10:43
02/20/19
02/20
10:43
02/20/19
10:43
Hot Stocks
Breaking Hot Stocks news story on Honeywell »

Honeywell says UOP will…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 20

    Feb

  • 29

    Apr

HON

Honeywell

$153.66

0.39 (0.25%)

10:41
02/20/19
02/20
10:41
02/20/19
10:41
Hot Stocks
Honeywell says UOP has been 'very disciplined' on the cost side »

Says Honeywell UOP…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 20

    Feb

  • 29

    Apr

FITB

Fifth Third

$27.49

-0.025 (-0.09%)

10:40
02/20/19
02/20
10:40
02/20/19
10:40
Options
Bearish option flow in Fifth Third Bancorp »

Bearish option flow in…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 28

    Feb

  • 12

    Mar

10:40
02/20/19
02/20
10:40
02/20/19
10:40
General news
Money market rates have dipped »

Money market rates have…

10:35
02/20/19
02/20
10:35
02/20/19
10:35
Conference/Events
Morgan Stanley sports/footwear analyst to hold analyst/industry conference call »

Sports & Footwear…

KO

Coca-Cola

$44.99

0.17 (0.38%)

10:30
02/20/19
02/20
10:30
02/20/19
10:30
Options
Vote of confidence in Coca Cola »

Vote of confidence in…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 20

    Feb

  • 03

    Mar

ARW

Arrow Electronics

$81.74

0.73 (0.90%)

10:28
02/20/19
02/20
10:28
02/20/19
10:28
Hot Stocks
Arrow Electronics CEO sells over $4.3M worth of shares »

Arrow Electronics CEO…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 03

    Mar

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.